- Home
- DNTH vs EYPT Comparison
DNTH vs EYPT Comparison
Compare DNTH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- EYPT
- Stock Information
- Founded
- DNTH 2015
- EYPT 1987
- Country
- DNTH United States
- EYPT United States
- Employees
- DNTH N/A
- EYPT N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- DNTH Health Care
- EYPT Industrials
- Exchange
- DNTH Nasdaq
- EYPT Nasdaq
- Market Cap
- DNTH 711.2M
- EYPT 594.5M
- IPO Year
- DNTH N/A
- EYPT 2005
- Fundamental
- Price
- DNTH $23.80
- EYPT $7.10
- Analyst Decision
- DNTH Strong Buy
- EYPT Strong Buy
- Analyst Count
- DNTH 9
- EYPT 8
- Target Price
- DNTH $46.43
- EYPT $27.29
- AVG Volume (30 Days)
- DNTH 203.7K
- EYPT 972.1K
- Earning Date
- DNTH 11-07-2024
- EYPT 11-07-2024
- Dividend Yield
- DNTH N/A
- EYPT N/A
- EPS Growth
- DNTH N/A
- EYPT N/A
- EPS
- DNTH N/A
- EYPT N/A
- Revenue
- DNTH $5,366,000.00
- EYPT $45,713,000.00
- Revenue This Year
- DNTH $98.73
- EYPT N/A
- Revenue Next Year
- DNTH N/A
- EYPT N/A
- P/E Ratio
- DNTH N/A
- EYPT N/A
- Revenue Growth
- DNTH 51.41
- EYPT 7.50
- 52 Week Low
- DNTH $8.24
- EYPT $6.90
- 52 Week High
- DNTH $33.77
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- DNTH 46.14
- EYPT 33.95
- Support Level
- DNTH $22.59
- EYPT $7.21
- Resistance Level
- DNTH $24.57
- EYPT $8.21
- Average True Range (ATR)
- DNTH 1.49
- EYPT 0.56
- MACD
- DNTH 0.04
- EYPT -0.08
- Stochastic Oscillator
- DNTH 30.84
- EYPT 8.58
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.